SEP
FLNA

Signature Equity Partners’s Filana Therapeutics FLNA Stock Holding History

Signature Equity Partners’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.38K Hold
2,000
– – ﹤0.01% 1035
2025
Q4 		$3.96K Buy
+2,000
New +$6.4K ﹤0.01% 1052

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Signature Equity Partners's FLNA Position: Q1 2026 in Review

Signature Equity Partners held its Filana Therapeutics (FLNA) position steady in Q1 2026 at 2,000 shares worth $3.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1035.

Signature Equity Partners first reported a position in FLNA in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.96K in Q4 2025. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Signature Equity Partners held 2,000 shares of Filana Therapeutics worth $3.38K as of Q1 2026.
  • Signature Equity Partners left its Filana Therapeutics share count unchanged in Q1 2026.
  • Filana Therapeutics made up ﹤0.01% of Signature Equity Partners's portfolio in Q1 2026, its #1035 holding.
  • Signature Equity Partners first reported a position in Filana Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Signature Equity Partners's Filana Therapeutics position peaked at $3.96K in Q4 2025.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.